We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+64.04%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$2.61B
AUM Growth
+$301M
Cap. Flow
-$35.3M
Cap. Flow %
-1.36%
Top 10 Hldgs %
53.33%
Holding
82
New
6
Increased
24
Reduced
27
Closed
10

Top Buys

Rank Stock Value
1
IMGN
Immunogen Inc
IMGN
+$114M
2
KRYS icon
Krystal Biotech
KRYS
+$66.7M
3
CTLT
CATALENT, INC.
CTLT
+$24.2M
4
COGT icon
Cogent Biosciences
COGT
+$23.6M
5
ZBH icon
Zimmer Biomet
ZBH
+$20.6M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$102M
2
ARGX icon
argenx
ARGX
+$48.6M
3
OSH
Oak Street Health, Inc.
OSH
+$41.1M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$31.9M
5
BMY icon
Bristol-Myers Squibb
BMY
+$31.2M

Sector Composition

Rank Sector Weight
1 Healthcare 97.11%
2 Industrials 2.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDVL
51
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
$8.48M 0.33%
692,090
– –
RAPT
52
DELISTED
RAPT Therapeutics
RAPT
$8.08M 0.31%
53,990
-32,027
-37% -$4.99M
SLRN
53
DELISTED
ACELYRIN
SLRN
$7.62M 0.29%
+364,493
New +$7.45M
STVN icon
54
Stevanato
STVN
$5.74B
$7.06M 0.27%
218,169
-683,763
-76% -$19.2M
KLRS
55
Kalaris Therapeutics
KLRS
$95.9M
$6.49M 0.25%
82,955
– –
EVH icon
56
Evolent Health
EVH
$520M
$6.47M 0.25%
+213,432
New +$6.9M
MRSN
57
DELISTED
Mersana Therapeutics
MRSN
$5.59M 0.21%
+67,945
New +$9.94M
GRFS
58
Grifois
GRFS
$5.23B
$5.5M 0.21%
600,684
-120,100
-17% -$991K
NUVB icon
59
Nuvation Bio
NUVB
$2.34B
$5.46M 0.21%
3,031,009
– –
SLGC
60
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$4.32M 0.17%
1,870,839
– –
LVTX
61
DELISTED
LAVA Therapeutics
LVTX
$4.21M 0.16%
2,074,372
– –
SNCE
62
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$4.21M 0.16%
990,412
– –
HOOK
63
DELISTED
HOOKIPA Pharma
HOOK
$2.89M 0.11%
328,847
+73,552
+29% +$817K
XERS icon
64
Xeris Biopharma Holdings
XERS
$1.55B
$2.74M 0.11%
1,046,587
– –
NVTA
65
DELISTED
Invitae Corporation
NVTA
$2.58M 0.1%
2,280,403
– –
NGNE icon
66
Neurogene
NGNE
$732M
$2.42M 0.09%
145,611
+53,231
+58% +$873K
ACHL
67
DELISTED
Achilles Therapeutics
ACHL
$1.52M 0.06%
1,608,089
– –
IVVD icon
68
Invivyd
IVVD
$284M
$1.51M 0.06%
1,440,725
– –
TKNO icon
69
Alpha Teknova
TKNO
$382M
$825K 0.03%
308,852
-64,392
-17% -$173K
SONX
70
DELISTED
Sonendo, Inc.
SONX
$677K 0.03%
498,131
– –
ADAP
71
DELISTED
Adaptimmune Therapeutics
ADAP
$662K 0.03%
+715,607
New +$853K
BCEL
72
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$434K 0.02%
442,653
– –
ARGX icon
73
argenx
ARGX
$64B
– –
-130,540
Closed -$48.6M
BMY icon
74
Bristol-Myers Squibb
BMY
$136B
– –
-449,442
Closed -$31.2M
CNC icon
75
Centene
CNC
$32B
– –
-277,351
Closed -$17.5M
1 2
3
4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q2 2023 Portfolio in Review

As of Q2 2023, Redmile Group held 82 positions worth $2.61B, up 13% from $2.3B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Redmile Group's Q2 2023 filing shows 6 new, 24 increased, 27 reduced and 10 closed positions. Its largest new stake was Cogent Biosciences: 2,053,333 shares worth $24.3M. The largest sale was IVERIC bio, Inc. Common Stock, an estimated $102M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 99% a quarter earlier, followed by Industrials.

  • Redmile Group's largest Q2 2023 buy was Cogent Biosciences: 2,053,333 shares worth $24.3M.
  • Redmile Group added most to Immunogen Inc in Q2 2023, an estimated $114M increase.
  • Redmile Group's biggest Q2 2023 reduction was Stevanato, cutting an estimated $19.2M.
  • Redmile Group fully exited IVERIC bio, Inc. Common Stock in Q2 2023, selling an estimated $102M.
  • Redmile Group's ten largest holdings make up 53% of its $2.61B portfolio in Q2 2023.
  • Redmile Group opened 6 new positions and closed 10 in Q2 2023.
  • Redmile Group's portfolio value rose 13% quarter-over-quarter to $2.61B.

Based on Redmile Group's 13F filing for Q2 2023, filed 14 Aug 2023.